Expanded Access Policy
Arvinas is a biotechnology company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.
Expanded access, also called compassionate use, refers to a pathway in which patients with serious or immediately life-threatening diseases may gain access to an investigational therapy outside the context of participation in clinical trials designed to evaluate safety and efficacy.
At this time, we do not have an expanded access program that allows patients to have access to our investigational products prior to FDA approval.
- If you have any questions about our expanded access policy, please contact Arvinas through the following email address: firstname.lastname@example.org.
- Information on all ongoing investigational trials sponsored by Arvinas can be found at clinicaltrials.gov
As authorized by the 21st Century Cures Act, Arvinas may revise this expanded access policy at any time. Additionally, the posting of this policy by Arvinas shall not serve as a guarantee of access to any specific investigational drug by any individual patient.